Shanghai Junshi Bioscience Co., Ltd.

This trial is testing whether combining two drugs—glumetinib and toripalimab—can help people with advanced non-small cell lung cancer that has not responded to or is no longer controlled by standard treatments. The study is enrolling adults whose cancer has a specific marker (PD-…

This phase 2 trial is testing whether toripalimab, an immunotherapy drug, can shrink tumors in people with advanced stomach or gastroesophageal junction cancer that has worsened after at least two prior treatments. Participants receive toripalimab every three weeks. The main goal…

This phase II trial tests whether toripalimab, an anti-PD-1 antibody, can prevent mucosal melanoma from returning after surgical removal better than high-dose interferon. Adults aged 18 to 75 whose melanoma was completely removed and who have not had prior adjuvant therapy are el…

This phase 2 trial tests an experimental drug called JS005 in Chinese adults with active non-radiographic axial spondyloarthritis, a form of inflammatory back pain that does not yet show damage on X-rays. Participants receive either a low, medium, or high dose of JS005 or a place…

This early-stage study tested a new drug (JS004) combined with another immunotherapy (Toripalimab) in 31 people with advanced solid tumors like liver, esophageal, stomach, cervical, or colorectal cancer. The goal was to check safety and see if the combination could help control t…